NASDAQ:DBVT - DBV Technologies Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $17.33 -0.85 (-4.68 %) (As of 07/20/2018 08:00 AM ET)Previous Close$18.18Today's Range$17.25 - $17.8852-Week Range$17.25 - $50.57Volume163,500 shsAverage Volume123,215 shsMarket Capitalization$1.04 billionP/E Ratio-5.14Dividend YieldN/ABeta1 Company ProfileFinancialsAnalyst RatingsEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France. Receive DBVT News and Ratings via Email Sign-up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:DBVT CUSIPN/A Webwww.dbv-technologies.com Phone33-1-55-42-78-78 Debt Debt-to-Equity Ratio0.01 Current Ratio4.37 Quick Ratio4.37 Price-To-Earnings Trailing P/E Ratio-5.14 Forward P/E Ratio-4.60 P/E GrowthN/A Sales & Book Value Annual Sales$13.45 million Price / Sales73.49 Cash FlowN/A Price / CashN/A Book Value$2.94 per share Price / Book5.89 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees244 Outstanding Shares57,040,000Market Cap$1,036.91 DBV Technologies (NASDAQ:DBVT) Frequently Asked Questions What is DBV Technologies' stock symbol? DBV Technologies trades on the NASDAQ under the ticker symbol "DBVT." How were DBV Technologies' earnings last quarter? DBV Technologies (NASDAQ:DBVT) posted its quarterly earnings data on Thursday, March, 26th. The company reported ($0.79) EPS for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.35. View DBV Technologies' Earnings History. What price target have analysts set for DBVT? 9 equities research analysts have issued 1 year target prices for DBV Technologies' stock. Their predictions range from $28.00 to $57.00. On average, they expect DBV Technologies' share price to reach $42.5714 in the next twelve months. This suggests a possible upside of 145.7% from the stock's current price. View Analyst Ratings for DBV Technologies. What is the consensus analysts' recommendation for DBV Technologies? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of DBV Technologies' key competitors? Some companies that are related to DBV Technologies include Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), argenx (ARGX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Repligen (RGEN), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), Solid Biosciences (SLDB) and Sangamo Therapeutics (SGMO). Who are DBV Technologies' key executives? DBV Technologies' management team includes the folowing people: Dr. Pierre-Henri Benhamou, Co-Founder, Chairman & CEO (Age 63)Mr. David Schilansky, Deputy CEO & Principal Financial Officer (Age 43)Mr. Bertrand Dupont, Co-Founder & CTO (Age 66)Mr. Charles Ruban, Chief Operating Officer (Age 46)Dr. Hugh A. Sampson, Chief Scientific Officer & Member of The Scientific Advisory Board (Age 69) Has DBV Technologies been receiving favorable news coverage? Media stories about DBVT stock have been trending somewhat positive on Friday, according to Accern. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. DBV Technologies earned a media sentiment score of 0.24 on Accern's scale. They also assigned media stories about the company an impact score of 47.11 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term. Who are DBV Technologies' major shareholders? DBV Technologies' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BPIFRANCE PARTICIPATIONS SA (11.00%). View Institutional Ownership Trends for DBV Technologies. How do I buy shares of DBV Technologies? Shares of DBVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is DBV Technologies' stock price today? One share of DBVT stock can currently be purchased for approximately $17.33. How big of a company is DBV Technologies? DBV Technologies has a market capitalization of $1.04 billion and generates $13.45 million in revenue each year. The company earns $-166,930,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. DBV Technologies employs 244 workers across the globe. How can I contact DBV Technologies? DBV Technologies' mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company can be reached via phone at 33-1-55-42-78-78. MarketBeat Community Rating for DBV Technologies (NASDAQ DBVT)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 215 (Vote Outperform)Underperform Votes: 192 (Vote Underperform)Total Votes: 407MarketBeat's community ratings are surveys of what our community members think about DBV Technologies and other stocks. Vote "Outperform" if you believe DBVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DBVT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: What does RSI mean?